ICAgen Inc.
4222 Emperor Boulevard
Suite 350
Durham,
NC 27703
Phone: 919-941-5206
Fax: 919-941-0813
Web Site: http://www.icagen.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The companys primary drug candidates include ICA-105665 that is in the Phase I multiple ascending dose study in healthy volunteers and epilepsy patients for epilepsy and neuropathic pain; and Senicapoc, which is in the Phase II proof-of-concept clinical trials for the treatment of asthma. It also engages in conducting ongoing drug discovery programs that focus on new therapeutics for pain and inflammatory disorders. Icagen, Inc. has a collaborative research and license agreement with Pfizer Inc. for the discovery, development, manufacture, and commercialization of compounds and products that modulate three specific sodium ion channels as new potential treatments for pain and related disorders. The company was founded in 1992 and is based in Durham, North Carolina. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Dr. P. Kay Wagoner Ph.D., 61
Co-Founder, Chief Exec. Officer, Pres |
N/A
| N/A | Dr. Richard D. Katz M.D, 46
Chief Financial Officer, Principal Accounting Officer, Exec. VP of Corp. Devel. & Fin. and Treasurer |
N/A
| N/A | Dr. Seth V. Hetherington M.D., 57
Sr. VP of Clinical & Regulatory Affairs |
N/A
| N/A | Mr. Robert J. Jakobs C.M.A, 55
Sr. Director of Fin., Sec. and Controller |
N/A
| N/A | Dr. Greg C. Rigdon Ph.D, 52
VP of New Product Devel. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.03 (3.77%)
Reuters offers more in-depth
